Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial

P. Bech, M. Fava, M. H. Trivedi, S. R. Wisniewski, A. J. Rush

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objective: To compare within the framework of a novel pharmacopsychometric triangle, augmentation treatment with bupropion vs. buspirone in the acute therapy of major depression in the STAR*D study. The triangle provides a composite view in three domains of antidepressive activity, side effects, and quality of life. Method: Within the pharmacopsychometric triangle, the short six-item subscales of the Hamilton Depression Scale (HAM-D17) and of the Inventory of Depressive Symptomatology (IDS-C30), referred to as HAM-D6 and IDS-C6, were focussed on pure antidepressive effect. Side-effects (tolerable vs. intolerable) and quality of life were measured using patient-administered questionnaires. A modified intention to treat sample was used. Results: Within the pharmacopsychometric triangle, bupropion-SR (sustained release) was superior to buspirone when augmented to the current citalopram treatment. Thus, in the domain of pure antidepressive effect, bupropion-SR was superior (P=0.05) on the HAM-D6, IDS-C6, and IDS-C30, but not on the HAM-D17. In the domain of side effects, the total scores on the Patient Rated Inventory of Side Effects (PRISE) were reduced significantly more by bupropion-SR than by buspirone (P=0.03). In the domain of quality of life, the total scores on the Quality of Life Enjoyment and Satisfaction Questionnaire (QLES-Q) showed a trend (P=0.10) from baseline to endpoint of a superiority for bupropion-SR compared with buspirone. Conclusion: In all domains of the pharmacopsychometric triangle, bupropion-SR was superior to buspirone as augmentation therapy in depressed outpatients not responding to citalopram.

Original languageEnglish (US)
Pages (from-to)342-348
Number of pages7
JournalActa Psychiatrica Scandinavica
Volume125
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Buspirone
Bupropion
Citalopram
Quality of Life
Depression
Equipment and Supplies
Therapeutics
Outpatients

Keywords

  • Bupropion-SR
  • Buspirone
  • Citalopram
  • HAM-D
  • IDS-C
  • Pharmacopsychometric triangle

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial. / Bech, P.; Fava, M.; Trivedi, M. H.; Wisniewski, S. R.; Rush, A. J.

In: Acta Psychiatrica Scandinavica, Vol. 125, No. 4, 04.2012, p. 342-348.

Research output: Contribution to journalArticle

@article{99af4fa3cd40409ea0fada4dc2ac74a2,
title = "Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial",
abstract = "Objective: To compare within the framework of a novel pharmacopsychometric triangle, augmentation treatment with bupropion vs. buspirone in the acute therapy of major depression in the STAR*D study. The triangle provides a composite view in three domains of antidepressive activity, side effects, and quality of life. Method: Within the pharmacopsychometric triangle, the short six-item subscales of the Hamilton Depression Scale (HAM-D17) and of the Inventory of Depressive Symptomatology (IDS-C30), referred to as HAM-D6 and IDS-C6, were focussed on pure antidepressive effect. Side-effects (tolerable vs. intolerable) and quality of life were measured using patient-administered questionnaires. A modified intention to treat sample was used. Results: Within the pharmacopsychometric triangle, bupropion-SR (sustained release) was superior to buspirone when augmented to the current citalopram treatment. Thus, in the domain of pure antidepressive effect, bupropion-SR was superior (P=0.05) on the HAM-D6, IDS-C6, and IDS-C30, but not on the HAM-D17. In the domain of side effects, the total scores on the Patient Rated Inventory of Side Effects (PRISE) were reduced significantly more by bupropion-SR than by buspirone (P=0.03). In the domain of quality of life, the total scores on the Quality of Life Enjoyment and Satisfaction Questionnaire (QLES-Q) showed a trend (P=0.10) from baseline to endpoint of a superiority for bupropion-SR compared with buspirone. Conclusion: In all domains of the pharmacopsychometric triangle, bupropion-SR was superior to buspirone as augmentation therapy in depressed outpatients not responding to citalopram.",
keywords = "Bupropion-SR, Buspirone, Citalopram, HAM-D, IDS-C, Pharmacopsychometric triangle",
author = "P. Bech and M. Fava and Trivedi, {M. H.} and Wisniewski, {S. R.} and Rush, {A. J.}",
year = "2012",
month = "4",
doi = "10.1111/j.1600-0447.2011.01791.x",
language = "English (US)",
volume = "125",
pages = "342--348",
journal = "Acta Psychiatrica Scandinavica",
issn = "0001-690X",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial

AU - Bech, P.

AU - Fava, M.

AU - Trivedi, M. H.

AU - Wisniewski, S. R.

AU - Rush, A. J.

PY - 2012/4

Y1 - 2012/4

N2 - Objective: To compare within the framework of a novel pharmacopsychometric triangle, augmentation treatment with bupropion vs. buspirone in the acute therapy of major depression in the STAR*D study. The triangle provides a composite view in three domains of antidepressive activity, side effects, and quality of life. Method: Within the pharmacopsychometric triangle, the short six-item subscales of the Hamilton Depression Scale (HAM-D17) and of the Inventory of Depressive Symptomatology (IDS-C30), referred to as HAM-D6 and IDS-C6, were focussed on pure antidepressive effect. Side-effects (tolerable vs. intolerable) and quality of life were measured using patient-administered questionnaires. A modified intention to treat sample was used. Results: Within the pharmacopsychometric triangle, bupropion-SR (sustained release) was superior to buspirone when augmented to the current citalopram treatment. Thus, in the domain of pure antidepressive effect, bupropion-SR was superior (P=0.05) on the HAM-D6, IDS-C6, and IDS-C30, but not on the HAM-D17. In the domain of side effects, the total scores on the Patient Rated Inventory of Side Effects (PRISE) were reduced significantly more by bupropion-SR than by buspirone (P=0.03). In the domain of quality of life, the total scores on the Quality of Life Enjoyment and Satisfaction Questionnaire (QLES-Q) showed a trend (P=0.10) from baseline to endpoint of a superiority for bupropion-SR compared with buspirone. Conclusion: In all domains of the pharmacopsychometric triangle, bupropion-SR was superior to buspirone as augmentation therapy in depressed outpatients not responding to citalopram.

AB - Objective: To compare within the framework of a novel pharmacopsychometric triangle, augmentation treatment with bupropion vs. buspirone in the acute therapy of major depression in the STAR*D study. The triangle provides a composite view in three domains of antidepressive activity, side effects, and quality of life. Method: Within the pharmacopsychometric triangle, the short six-item subscales of the Hamilton Depression Scale (HAM-D17) and of the Inventory of Depressive Symptomatology (IDS-C30), referred to as HAM-D6 and IDS-C6, were focussed on pure antidepressive effect. Side-effects (tolerable vs. intolerable) and quality of life were measured using patient-administered questionnaires. A modified intention to treat sample was used. Results: Within the pharmacopsychometric triangle, bupropion-SR (sustained release) was superior to buspirone when augmented to the current citalopram treatment. Thus, in the domain of pure antidepressive effect, bupropion-SR was superior (P=0.05) on the HAM-D6, IDS-C6, and IDS-C30, but not on the HAM-D17. In the domain of side effects, the total scores on the Patient Rated Inventory of Side Effects (PRISE) were reduced significantly more by bupropion-SR than by buspirone (P=0.03). In the domain of quality of life, the total scores on the Quality of Life Enjoyment and Satisfaction Questionnaire (QLES-Q) showed a trend (P=0.10) from baseline to endpoint of a superiority for bupropion-SR compared with buspirone. Conclusion: In all domains of the pharmacopsychometric triangle, bupropion-SR was superior to buspirone as augmentation therapy in depressed outpatients not responding to citalopram.

KW - Bupropion-SR

KW - Buspirone

KW - Citalopram

KW - HAM-D

KW - IDS-C

KW - Pharmacopsychometric triangle

UR - http://www.scopus.com/inward/record.url?scp=84858153468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858153468&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0447.2011.01791.x

DO - 10.1111/j.1600-0447.2011.01791.x

M3 - Article

C2 - 22077211

AN - SCOPUS:84858153468

VL - 125

SP - 342

EP - 348

JO - Acta Psychiatrica Scandinavica

JF - Acta Psychiatrica Scandinavica

SN - 0001-690X

IS - 4

ER -